Akebia Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Akebia Therapeutics

25/08/2023 14:31

* Akebia Therapeutics Inc  AKBA.OQ  reported a quarterly
adjusted
loss of 6 cents​​ per share for the quarter ended in June. The
mean expectation of two analysts for the quarter was for a loss
of 2 cents per share.
    * Revenue fell 55.5% to $56.38 million from a year ago;
analysts
expected $59.10 million. 
    * Akebia Therapeutics Inc's reported EPS for the quarter was
a
loss of 6 cents​.
    * The mean earnings estimate of analysts had risen by
about 16.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Akebia Therapeutics Inc shares had risen by 36.6% this
quarter and gained 116.6% so far this year.
    * The company reported a quarterly loss of $11.17 million.
    * Wall Street's median 12-month price target for Akebia
Therapeutics Inc is $3.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
August 25 at 01:31 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2023      -0.02          -0.06          Missed
 Mar. 31 2023      -0.15          -0.14          Beat
 Dec. 31 2022      -0.19          -0.04          Beat
 Sep. 30 2022      -0.15          -0.28          Missed